Datasets:

---

Recag

/

Rp_CommonC_317

like 0

ERROR: type should be string, got "https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvNDM1ODg0LXRyZWF0bWVudA==\nPremature Ejaculation Treatment & Management\nAuthor: Samuel G Deem, DO; Chief Editor: Edward David Kim, MD, FACS more...\nSections Premature Ejaculation\nCounseling and Sex Therapy\nOther Therapy\nTopical anesthetic agents\nPhosphodiesterase Type 5 Inhibitors\nBeta-adrenergic Blocker\nAnalgesic, Opioid\nMedical treatment for premature (early) ejaculation includes several options. Any serious primary medical condition (eg, angina) should be treated; for the purposes of the following discussion, the patient is assumed to be healthy, and premature ejaculation is assumed to be his only problem. In addition, any accompanying erection problem (eg, erectile dysfunction) should be treated; various methods are available, and excellent success can be expected. Accordingly, treatment of concomitant erectile dysfunction (ED) is mentioned only in passing. [21]\nTo achieve the best outcome, the female partner should be included as fully as possible in the treatment and counseling sessions. Pharmacologic therapy may include selective serotonin reuptake inhibitors (SSRIs) or topical desensitizing agents.\nOutpatient care can be scheduled as appropriate for the clinical circumstances.\nTo date, no drug has been specifically approved by the US Food and Drug Administration (FDA) for the treatment of premature ejaculation. However, numerous studies have shown that selective serotonin reuptake inhibitors (SSRIs) and drugs with SSRI-like side effects are safe and effective to treat this condition, and many physicians use these agents for this purpose. Topical desensitizing therapy with local anesthetic agents can also be useful in some men with premature ejaculation.\nPremature ejaculation that relates to erectile dysfunction may resolve if the erectile dysfunction is treated successfully. If a patient has depression-related erectile dysfunction but not premature ejaculation, a drug with minimal adverse sexual effects might be considered so as to avoid causing delayed ejaculation or even anorgasmia. [22] However, if the patient has premature ejaculation, erectile dysfunction, and depression, an antidepressant with SSRI side effects has the added benefit of possibly alleviating the premature ejaculation. [23]\nDesensitizing agents\nIn Korea and other areas of the Far East, SS (Super Secret) cream (a combination of 9 ingredients, mainly herbal) has been shown to desensitize the penis, decrease the vibratory threshold, and help men with premature ejaculation to delay their ejaculatory response significantly. [24, 25] This preparation is not yet approved by the FDA.\nSimple combinations of lidocaine cream or related topical anesthetic agents can also be effective. These combinations are safe as long as the patient has no history of allergy to the substance. [26, 27, 28, 29] A metered-dose lidocaine-prilocaine cutaneous spray (Fortacin) is approved in Europe. [30]\nSelective serotonin reuptake inhibitors and similar agents\nThe most effective pharmacologic therapy for premature ejaculation is to administer a drug from the SSRI class. Normally, these drugs are used as antidepressants in the clinical setting. Many of these agents were found to have the side effect of significantly delaying the achievement of orgasm in both male and female patients, and it was for this reason that such agents were applied to the treatment of premature ejaculation.\nSome tricyclic antidepressants (TCAs) with SSRI-like activity have the same effect in orgasm that SSRIs do. The TCA that has been most frequently studied for treatment of premature ejaculation is clomipramine. [31, 32, 33, 34, 35] Many investigators find that clomipramine is more effective for premature ejaculation than many SSRIs are. Results of a multicenter, randomized, double-blind, placebo-controlled, fixed-dose clinical phase III study in 159 Korean patients suggest that 15 mg of clomipramine taken approximately 2-6 hours before sexual intercourse is effective and safe for treatment of premature ejaculation. [36]\nIn most cases, females require considerably more time to reach climax than males do; thus, in females taking SSRIs and SSRI-like agents, the delayed climax caused by these agents becomes an adverse effect. In many females, such an inability to reach orgasm can induce a pattern of sexual avoidance, along with a corresponding decrease in libido or sexual excitement (lubrication). In males, too-rapid orgasm can cause some of the same patterns of sexual avoidance and decreased libido. Thus, it is essential to determine the primary problem when instituting therapy.\nSSRIs useful for treating premature ejaculation include the following:\nDapoxetine, which is generally categorized as a fast-acting SSRI, was developed specifically to treat this condition. It may be effective at the first dose (ie, on demand) when given 1-3 hours before sexual intercourse, and its adverse-effect profile is comparable to those of other SSRIs. [37, 38, 39] Dapoxetine has been approved in a number of countries but not yet in the United States. In a study of men with both premature ejaculation and erectile dysfunction who were on phosphodiesterase type 5 (PDE5) therapy, dapoxetine provided treatment benefit and was generally well tolerated. [40] However, up to 90% of patients discontinue dapoxetine, mostly because of adverse effects, cost, and disappointing efficacy. [30]\nThe optimal medical treatment regimen for premature ejaculation has not been established. The author’s experience has been that in some males, single dosing before sexual relations can work well, whereas in others, it may be necessary to achieve and maintain a target blood level through daily use of the medication, as in the treatment of clinical depression.\nObviously, if single dosing is successful, therapy is simpler and has fewer adverse effects. Accordingly, this may be the preferred initial approach. If necessary, the dose may be increased in a stepwise fashion until a therapeutic effect is achieved or the maximum daily recommended dose is reached. No exact schedule for increasing the dose has been established; the experience of the physician, the response of the patient, the adverse effects experienced by the patient, and other general medical considerations should be the guiding factors.\nIf the initial SSRI fails to help the patient, it is certainly reasonable to try a second agent. However, if the second choice fails, it is not likely that a third choice will offer any benefit. As with treatment for depression, if a patient has been taking the maximal dose of the medication for 6 weeks without showing any improvement, the likelihood that a more prolonged course of therapy with a particular drug would be successful is remote.\nThere is no reason why pharmacotherapy cannot be combined with behavioral modification therapy, desensitizing creams, or both; the use of several simultaneous treatments can result in additive effects or even synergy. If all treatment fails, then the patient’s only options are as follows:\nTo see a different health care professional, if he wishes\nTo accept his condition as being untreatable with currently available therapeutic options\nAdverse effects of long-term SSRI use are a significant concern and should be considered by both the physician and the patient. [41] Such adverse effects may include the following:\nPsychiatric and neurologic sequelae\nDermatologic reactions\nAnticholinergic effects\nFluctuation in body weight\nSexual side effects other than delayed ejaculation (eg, erectile dysfunction or loss of libido)\nIn addition, caution should be exercised in changing SSRIs; a washout period is necessary to avoid overdose. SSRI discontinuance syndrome (especially with paroxetine) has been associated with dose reduction or discontinuance and may cause dizziness, nausea and vomiting, headache, gait instability, lethargy, agitation, anxiety, and insomnia. [42]\nSome studies have demonstrated that combining phosphodiesterase type 5 (PDE5) inhibitors with SSRIs provides better results in the treatment of premature ejaculation than using SSRIs alone. [43] The reason for this is unknown, but part of the explanation may be that the improved (firmer, longer-lasting, or both) erection resulting from the PDE5 inhibitor provides inhibition of ejaculation via downregulation of receptors involved in somatosensory latency times. In addition, a reduction in performance anxiety may exist on a subconscious level.\nRegardless of the mechanism, PDE5 inhibitors have been found to be safe and effective as a therapeutic adjunct for premature ejaculation in men for whom such therapy is not otherwise contraindicated. The only PDE5 inhibitors studied to any significant degree in the setting of premature ejaculation are sildenafil and tadalafil [44, 45] ; vardenafil may also work, but the available data are insufficient to support its use.\nA single-blind randomized placebo-controlled clinical study in 100 patients concluded that tadalafil, 5 mg once daily for 6 weeks, was significantly more effective than placebo (P=0.001) and was well tolerated in the treatment of premature ejaculation. [46] Similarly, a meta-analysis of 15 randomized clinical trials suggests that PDE5-Is are significantly more effective than placebo (231 participants; P < 0.00001), that there is no difference between PDE5-Is and selective serotonin reuptake inhibitors (SSRIs; 405 participants, P = 0.50), and that PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone (521 participants, P = 0.001). [47] The use of PDE5 inhibitors for the treatment of premature ejaculation is not approved by the FDA and is considered an off-label use.\nOther agents\nA study by Safarinejad demonstrated that a single daily high dose of pindolol (a nonselective beta-adrenergic antagonist with 5-HT1A autoreceptor antagonist properties [48] ) in combination with paroxetine (or possibly another SSRI) delayed ejaculation in patients in whom paroxetine therapy alone failed to provide benefit. [49] However, more studies must be performed before pindolol can be considered an ideal option for first- or second-line treatment of premature ejaculation.\nIn studies by Safarinejad and Hosseini [50] and Salem et al, [51] the opioid analgesic tramadol was found to be significantly more effective than placebo in terms of increased time to ejaculation, increased sexual intercourse satisfaction, and tolerability. In a randomized double-blind, placebo-controlled clinical trial by Hamidi-Madani et al in 150 patients, 12 weeks of tramadol 50 mg on demand, paroxetine 20 mg on demand, and placebo all resulted in improvement, but the tramadol group experienced significantly greater benefit than the paroxetine and placebo groups (P < 0.0001). [52]\nA systematic review and meta-analysis found that tramadol may be effective in treatment of premature ejaculation, especially when other therapies have failed, but that it remains necessary to consider the possibility of drug addiction and adverse effects before initial use or after long-term use. [53]\nThe first step is to attempt to relieve any underlying performance pressure on the male. If premature ejaculation occurs when intercourse is attempted, the couple should be instructed not to attempt intercourse until the ejaculatory problem is treated. In the meantime, the male may use manual stimulation, oral sex, or other means to satisfy the female partner.\nIf the male always experiences ejaculation with initial sexual excitement or early foreplay, this is a serious problem and probably indicates lifelong premature ejaculation (the history should reveal this). Such cases will most likely call for treatment in conjunction with a mental health care professional. These more difficult cases should be screened out.\nNext, the couple should be instructed in sex therapy techniques, such as the stop-start or squeeze-pause technique popularized by Masters and Johnson. [1]\nIn this technique, the female partner slowly begins stimulation of the male but stops as soon as he senses a feeling of excessive excitement that may lead to ejaculatory inevitability. She then administers firm compression to the penis just behind the glans, pressing mainly on the underside. This compression should be uncomfortable but not painful. Once the male has the feeling that ejaculation is no longer imminent, the female resumes stimulation.\nThe process should be repeated and practiced at least 10 or more times. Over time, most males find that this technique helps decrease the impending inevitable need to ejaculate.\nAfter practicing this technique for a while, the couple can move to another phase of the process. In this phase, the partners sit facing each other, with the woman’s legs crossing on top of the male’s legs. She stimulates him by manipulating his penis first close to and then with friction against her vulval area. Each time he senses excessive excitement, she applies the squeeze and stops all stimulation until he calms down enough for the process to be repeated.\nFinally, coitus may be attempted, with the female partner in the superior position so that she may withdraw immediately and again apply a squeeze to remove the male partner’s urge to climax.\nMost couples find this technique to be highly successful. It can also help the female partner to be more aroused and can shorten her time to climax because it constitutes a form of extended foreplay in many cases.\nOther nonpharmacologic approaches may be helpful. If the male is relatively young and can achieve another erection within a few minutes after a premature ejaculation, he may find that he is much less likely to experience a premature ejaculation the second time. The interval for achieving a second climax often includes a much longer period of latency, and the male can usually exert better control in this setting.\nAccordingly, some therapists advise young men to masturbate (or have their partner stimulate them rapidly to climax) 1-2 hours before sexual relations are planned. In an older man, such a strategy may be less effective, because the older man may have difficulty achieving a second erection after his first rapid sexual release. If this occurs, it can damage his confidence and may result in secondary impotence.\nKilinc et al reported that moderate physical activity longer than 30 min at least 5 times a week leads to ejaculation delay in patients with premature ejaculation. In their study, 35 patients were treated with dapoxetine, 30 mg on demand; 35 performed moderate physical activities; and 35 performed minimal physical activity.. [54]\nPastore et al reported long-term benefit from pelvic muscle floor rehabilitation (PFM) in patients with lifelong premature ejaculation. The 154 participants in this retrospective study entered a 12-week program of PFM rehabilitation, including physio-kinesiotherapy treatment, electrostimulation, and biofeedback, with three sessions per week, with 20 min for each component completed at each session. Of the 122 participants who completed PFM rehabilitation, 111 gained control of their ejaculation reflex. Of the 95 participants who completed follow-up, 64% maintained satisfactory ejaculation control at 24 months and 56% did so at 36 months. [55]\nNo recommended surgical treatment exists for premature ejaculation.\nBefore the availability of nonsurgical methods for treating erectile dysfunction, a patient with premature ejaculation who was mistakenly diagnosed with erectile dysfunction might have undergone a penile prosthesis implantation, which would have yielded unsatisfactory results because of the incorrect initial diagnosis. In this scenario, the patient would be able to engage in sexual intercourse, because the penile implant would provide an adequate erection, but he would still climax prematurely.\nCurrently, penile implants are placed much more rarely, and with the use of nonsurgical treatments for erectile dysfunction, any permanent harm resulting from diagnosing erectile dysfunction rather than premature ejaculation is unlikely.\nConsultation with a sex therapist, psychologist, or psychiatrist may prove helpful if the primary care physician or urologist cannot provide successful treatment or does not have the time to explore psychological issues and implement behavioral techniques (eg, squeeze-pause). If the primary care physician or urologist is inexperienced or uncomfortable with treating premature ejaculation, early referral to a sex therapist, psychologist, or psychiatrist is indicated.\nSome physicians are comfortable implementing pharmacologic therapy but not behavioral therapy. As with any medical condition, the patient should be offered all available treatment options, and the physician should proceed with referral for any option considered to require more specialized help than the physician can provide.\nFor men who may have a severe emotional disturbance underlying the premature ejaculation, referral to a mental health professional is most appropriate. Diagnosis and treatment of the various psychological factors that manifest partly as premature ejaculation are beyond the scope of this discussion.\nMasters WH, Johnson VE. Premature ejaculation. Human Sexual Inadequacy. Boston, Mass: Little Brown & Company; 1970. 92-115.\nSerefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014 Jun. 11 (6):1423-41. [Medline].\nAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: APA Press; 2013.\nBuvat J. Pathophysiology of premature ejaculation. J Sex Med. 2011 Oct. 8 Suppl 4:316-27. [Medline].\nCanat L, Değirmentepe RB, Atalay HA, Alkan İ, Özbir S, Çulha MG, et al. The relationship between female sexual function index domains and premature ejaculation. Int Urol Nephrol. 2018 Apr. 50 (4):633-637. [Medline].\nYang X, Gao M, Zhang L, Liu L, Liu P, Sun J, et al. Central Neural Correlates During Inhibitory Control in Lifelong Premature Ejaculation Patients. Front Hum Neurosci. 2018. 12:206. [Medline]. [Full Text].\nPeeters M, Giuliano F. Central neurophysiology and dopanergic control of ejaculation. Neurosci Biobehav Rev. 2008. 32(3):438-53. [Medline].\nYusof F, Sidi H, Das S, Midin M, Kumar J, Hatta MH. Understanding the Pathophysiology of Premature Ejaculation: Bridging the Link between Pharmacological and Psychological Interventions. Curr Drug Targets. 2018. 19 (8):856-864. [Medline].\nCorona G, Jannini EA, Mannucci E et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. August 2008. 8:1991-8. [Medline].\nYao B, Li XY, Zhao ZM et al. Semen biochemical markers and their significance in the patients with premature ejaculation. Zhonghua Nan Ke Xue. December 2007. 13(12):1084-6. [Medline].\nCorona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, et al. Hypoprolactinemia: A New Clinical Syndrome in Patients with Sexual Dysfunction. J Sex Med. 2009 Feb 10. [Medline].\nPatrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005 May. 2(3):358-67. [Medline].\nPatrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: the central role of perceived control. J Sex Med. 2007 May. 4(3):780-8. [Medline].\nVerma KK, Khaitan BK, Singh OP. The frequency of sexual dysfunctions in patients attending a sex therapy clinic in north India. Arch Sex Behav. 1998 Jun. 27(3):309-14. [Medline].\nLee SW, Lee JH, Sung HH, Park HJ, Park JK, Choi SK, et al. The prevalence of premature ejaculation and its clinical characteristics in Korean men according to different definitions. Int J Impot Res. 2013 Jan. 25 (1):12-7. [Medline].\nGiuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008 May. 53(5):1048-57. [Medline].\nFrewen A, Rapee RM, Bowden P, Lagios K. Regional differences in men attending a sexual health clinic in Sydney for premature ejaculation. J Sex Med. 2007 Nov. 4(6):1733-8. [Medline].\n[Guideline] Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014 Jun. 11 (6):1392-422. [Medline]. [Full Text].\nCorona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2015 Dec. 12 (12):2291-300. [Medline].\nLee JH, Lee SW. Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. J Sex Med. 2015 Mar. 12 (3):697-704. [Medline].\nMohee A, Eardley I. Medical therapy for premature ejaculation. Ther Adv Urol. 2011 Oct. 3(5):211-22. [Medline]. [Full Text].\nKilic S, Ergin, H, Baydinc YC. Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. Int J Androl. 2005. 28:47. [Medline].\nPorst H. An overview of pharmacotherapy in premature ejaculation. J Sex Med. 2011 Oct. 8 Suppl 4:335-41. [Medline].\nChoi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000 Feb. 55(2):257-61. [Medline].\nXin ZC, Choi YD, Seong DH, Choi HK. Sensory evoked potential and effect of SS-cream in premature ejaculation. Yonsei Med J. 1995 Nov. 36(5):397-401. [Medline].\nBusato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004 May. 93(7):1018-21. [Medline].\nHenry R, Morales A. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res. 2003 Aug. 15(4):277-81. [Medline].\nBerkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995 Oct. 154(4):1360-1. [Medline].\nPu C, Yang L, Liu L, Yuan H, Wei Q, Han P. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology. 2013 Apr. 81(4):799-804. [Medline].\nPorst H, Burri A. Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review. Sex Med Rev. 2018 Jul 26. [Medline].\nColpi GM, Fanciullacci F, Aydos K, Grugnetti C. Effectiveness mechanism of chlomipramine by neurophysiological tests in subjects with true premature ejaculation. Andrologia. 1991 Jan-Feb. 23(1):45-7. [Medline].\nGirgis SM, El-Haggar S, El-Hermouzy S. A double-blind trial of clomipramine in premature ejaculation. Andrologia. 1982 Jul-Aug. 14(4):364-8. [Medline].\nGoodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1980. 8 Suppl 3:53-9. [Medline].\nHaensel SM, Rowland DL, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996 Oct. 156(4):1310-5. [Medline].\nKim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol. 1998 Feb. 159(2):425-7. [Medline].\nChoi JB, Kang SH, Lee DH, Kim YS, Jeon JS, Choi WS, et al. Efficacy and Safety of On-Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial. J Urol. 2018 Aug 4. [Medline].\nPryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9. 368(9539):929-37. [Medline].\nSafarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006 Sep-Oct. 29(5):243-52. [Medline].\nSafarinejad MR. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008 May. 33(6):1259-65. [Medline].\nMcMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, et al. Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study. J Sex Med. 2013 Jul 11. [Medline].\nGiuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int. 2008 Sep. 102(6):668-75. [Medline].\nBlack K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000 May. 25(3):255-61. [Medline].\nAbdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs. 2004. 64(1):13-26. [Medline].\nMattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008. 80(2):162-5. [Medline].\nChen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol. 2007 Nov. 52(5):1331-9. [Medline].\nAbu El-Hamd M. Efficacy and safety of daily use of tadalafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia. 2018 Jun. 50 (5):e13005. [Medline].\nMartyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, et al. Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. Eur Urol Focus. 2017 Feb. 3 (1):119-129. [Medline]. [Full Text].\nBlier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 1997 May. 16(5):333-8. [Medline].\nSafarinejad MR. Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. J Clin Psychopharmacol. 2008 Feb. 28(1):39-44. [Medline].\nSafarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006 Feb. 26(1):27-31. [Medline].\nSalem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008 Jan. 5(1):188-93. [Medline].\nHamidi-Madani A, Motiee R, Mokhtari G, Nasseh H, Esmaeili S, Kazemnezhad E. The Efficacy and Safety of On-demand Tramadol and Paroxetine Use in Treatment of Life Long Premature Ejaculation: A Randomized Double-blind Placebo-controlled Clinical Trial. J Reprod Infertil. 2018 Jan-Mar. 19 (1):10-15. [Medline].\nYang L, Qian S, Liu H, Liu L, Pu C, Han P, et al. Role of Tramadol in Premature Ejaculation: A Systematic Review and Meta-Analysis. Urol Int. 2013 Jun 6. [Medline].\nKilinc MF, Aydogmus Y, Yildiz Y, Doluoglu OG. Impact of physical activity on patient self-reported outcomes of lifelong premature ejaculation patients: Results of a prospective, randomised, sham-controlled trial. Andrologia. 2018 Feb. 50 (1):[Medline].\nPastore AL, Palleschi G, Fuschi A, Al Salhi Y, Zucchi A, Bozzini G, et al. Pelvic muscle floor rehabilitation as a therapeutic option in lifelong premature ejaculation: long-term outcomes. Asian J Androl. 2018 Jul 3. [Medline]. [Full Text].\n[Guideline] Stanley E. Althof, Ph.D1., Chris G. McMahon, M.D.2, Marcel D. Waldinger, M.D., et al. An Update of the International Society of Sexual Medicine’s Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). International Society for Sexual Medicine. Available at https://www.issm.info/images/uploads/PE_Guidelines_v12_-_FEB_2014.pdf. February 2014; Accessed: September 25, 2018.\n[Guideline] Drogo K. Montague, MD, Co-Chairman; Jonathan Jarow, MD, Co-Chairman; Gregory A. Broderick, MD; Roger R. Dmochowski, et al. Pharmacologic Management of Premature Ejaculation. AUA Clinical Guidelines. Available at http://www.auanet.org/guidelines/premature-ejaculation-(2004-reviewed-and-validity-confirmed-2010). 2010; Accessed: 8/6/2017.\nDavid Prologo J, Snyder LL, Cherullo E, Passalacqua M, Pirasteh A, Corn D. Percutaneous CT-guided Cryoablation of the Dorsal Penile Nerve for Treatment of Symptomatic Premature Ejaculation. J Vasc Interv Radiol. 2013 Feb. 24(2):214-9. [Medline].\nSamuel G Deem, DO Faculty, Department of Urology, Charleston Area Medical Center\nSamuel G Deem, DO is a member of the following medical societies: American College of Surgeons, American Osteopathic Association, American Urological Association, Endourological Society, Society of Urologic Oncology, American Society of Clinical Oncology, American College of Osteopathic Surgeons\nKevin P Brown, DO Resident Physician, Department of Urology, Charleston Area Medical Center\nKevin P Brown, DO is a member of the following medical societies: American Osteopathic Association, American Urological Association\nAaron Benson, MD Staff Physician, Department of Surgery, Division of Urology, Southern Illinois University School of Medicine\nAaron Benson, MD is a member of the following medical societies: American Medical Association, American Urological Association, and Illinois State Medical Society\nDisclosure: Nothing to disclose. Leonard Gabriel Gomella, MD, FACS The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University\nLeonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, Society for Basic Urologic Research, Society of University Urologists, and Society of Urologic Oncology\nDisclosure: GSK Consulting fee Consulting; Astra Zeneca Honoraria Speaking and teaching; Watson Pharmaceuticals Consulting fee Consulting\nMilton Lakin, MD Head, Section of Medical Urology, Urological Institute, Cleveland Clinic\nMilton Lakin, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, and American Urological Association\nMark Jeffrey Noble, MD Consulting Staff, Urologic Institute, Cleveland Clinic Foundation\nMark Jeffrey Noble, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Kansas Medical Society, Sigma Xi, Society of University Urologists, and Southwest Oncology Group\nLoren B Ost, MD Associate Professor, Department of Surgery, Southern Illinois University School of Medicine; Urologist, SIU Physicians and Surgeons\nLoren B Ost, MD is a member of the following medical societies: American Urological Association\nencoded search term (Premature Ejaculation) and Premature Ejaculation\nFast Five Quiz: How Much Do You Know About Erectile Dysfunction?\nPenis Anatomy\nPenile Prosthesis Implantation\nA 58-Year-Old Man Has No Difficulty With Orgasm or Ejaculation but Cannot Maintain an Erection\nHow Is Antidepressant-Associated Sexual Dysfunction Managed?\nRemove a Penicillin Allergy Label: Safe, and Saves Money\nOff Gurneys, Into Beds -- How Can We Speed Up Admissions?\n'T'errific or 'T'errible? A Review of Testosterone Deficiency and Its Management\nDiseases & Conditions Erectile Dysfunction\n2010 adcirca-cialis-tadalafil-342873 Drugs\nDrugs tadalafil\n2010 caverject-edex-alprostadil-342846 Drugs\nDrugs alprostadil intracavernous/urethral\nNews Erectile Dysfunction Common in Childhood Cancer Survivors"